APA (7th ed.) Citation

Carbone, D. P., McKean, M., Balaraman, R., Shah, S., Arrowsmith, E., Peguero, J. A., . . . Li, T. (2023). Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy. Journal of clinical oncology, 41(16_suppl), 9024. https://doi.org/10.1200/JCO.2023.41.16_suppl.9024

Chicago Style (17th ed.) Citation

Carbone, David Paul, et al. "Safety and Clinical Activity of Target-preserving Anti-CTLA-4 Antibody ONC-392 as Monotherapy in NSCLC Patients Who Progressed on PD(L)1-targeted Immunotherapy." Journal of Clinical Oncology 41, no. 16_suppl (2023): 9024. https://doi.org/10.1200/JCO.2023.41.16_suppl.9024.

MLA (9th ed.) Citation

Carbone, David Paul, et al. "Safety and Clinical Activity of Target-preserving Anti-CTLA-4 Antibody ONC-392 as Monotherapy in NSCLC Patients Who Progressed on PD(L)1-targeted Immunotherapy." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. 9024, https://doi.org/10.1200/JCO.2023.41.16_suppl.9024.